Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HitGenSHSE:688222 +3.04%90 EBITDA Margin % is 30.08% as of Mar. 2026, which is 4% below its 10-year median of 31.30. GuruFocus rates SHSE:688222 with a GF Score™ of 90/100 and a GF Value™ of ¥26.07 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 940 Biotechnology companies, HitGen ranks better than 86.49% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. HitGen's EBITDA for the
three
months ended in Mar. 2026 was ¥48.3 Mil. HitGen's Revenue for the
three
months ended in Mar. 2026 was ¥160.5 Mil. Therefore, HitGen's EBITDA margin for the quarter that ended in Mar. 2026 was 30.08%.
HitGen (SHSE:688222) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
HitGen EBITDA Margin % Related Terms
HitGen EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for HitGen's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688222 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, HitGen's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HitGen EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HitGen's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where HitGen's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HitGen (SHSE:688222) has a EBITDA Margin % of 30.08% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on HitGen and its competitors. This is near median its historical median of 31.30. According to the industry distribution chart, HitGen ranks #127 out of 940 companies in the Biotechnology industry, placing it in the top 13.5%.
Is HitGen's EBITDA Margin % too high?
HitGen's current EBITDA Margin % of 30.08% is near median its 10-year median of 31.30. Based on the distribution chart, HitGen ranks #127 out of 940 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, HitGen has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does HitGen's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HitGen ranks #127 out of 940 companies for EBITDA Margin %. This places HitGen in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on HitGen and its competitors. HitGen's current EBITDA Margin % is 30.08%, which is near median its own 10-year median of 31.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HitGen stock overvalued right now?
Based on GuruFocus' analysis, HitGen (SHSE:688222) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥26.07, compared to a current price of ¥29.16 — trading 11.9% above its estimated fair value. The current EBITDA Margin % is 30.08%, which is near median its 10-year median of 31.30. HitGen's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For HitGen (SHSE:688222), the current EBITDA Margin % is 30.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HitGen (SHSE:688222) Overvalued in 2026?
Based on GuruFocus' analysis, HitGen stock appears to be overvalued.
The current stock price of ¥29.16 is trading 11.9% above its estimated GF Value™ of ¥26.07.
GuruFocus considers HitGen to be Modestly Overvalued.
Key valuation signals for SHSE:688222:
EBITDA Margin %: 30.08% (near median its 10-year median of 31.30)
GF Value™: ¥26.07 vs. price of ¥29.16 (11.9% above fair value)
No single metric tells the full story. See the SHSE:688222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HitGen Inc is dedicated to building a world-class biopharmaceutical enterprise. Its mission is to advance human health and quality of life. It provides therapeutic solutions to address unmet medical needs. Centered on its internationally DEL (DNA-encoded Library) technology, the Company has expanded into Fragment-Based Drug Discovery and Structure-Based Drug Design and a suite of complementary platforms based on Oligonucleotide-based Therapeutics, Targeted Proximity Drugs, and Cyclic Peptidomimetics. The group has developed HAILO, a proprietary "DEL+AI+Automation" molecular optimization platform, thereby establishing a distinctive novel molecule discovery engine that delivers both therapeutic molecules and tool molecules to the world-wide pharmaceutical industry.
90GF Score
Get the complete analysis for SHSE:688222
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688222 has been successfully added to your 
